Showing 521-530 of 1781 results for "".
The Cost-Benefit Calculus of CT Angiograms
https://reachmd.com/programs/heart-matters/the-cost-benefit-calculus-of-ct-angiograms/4047/Measuring precise risks in medicine can be a tricky proposition. Factoring risk into cost-benefit analyses can make the situation even less clear. In many ways, this is where we stand with coronary computed tomography angiograms: a scan can be immediately helpful in emergent circumstances, but at otLipid Lowering: The End or the Means to Better CV Results?
https://reachmd.com/programs/lipid-luminations/lipid-lowering-the-end-or-the-means-to-better-cv-results/4359/The answer almost assuredly is patient-specific, but the question of lipid-lowering as the end or the means in measuring cardiovascular risk highlights the ongoing discussion in medicine about targets: whether how we get there is more important than just getting there. Dr. Roger Blumenthal, professoDiagnosing Non-Arthritic Hip Pain in Athletes
https://reachmd.com/programs/focus-on-sports-medicine/diagnosing-non-arthritic-hip-pain-in-athletes/3800/In sports medicine, the hip has traditionally received less attention from physicians than other joints. What are the types of non-arthritic hip pain that clinicians need to recognize in order to make accurate diagnoses for both recreational and professional athletes? Dr. Brian Kelly, assistant profNot Quite a Cancer Vaccine: Selling HPV & Cervical Cancer
https://reachmd.com/programs/project-oncology/not-quite-a-cancer-vaccine-selling-hpv-and-cervical-cancer/10028/Samantha Gottlieb traces the medical, social, and political controversies in the ten years following the HPV vaccine's launch.Harnessing DED Data: Emerging Therapies, Pipeline, and Cases
https://reachmd.com/clinical-practice/optometry/harnessing-ded-data-emerging-therapies-pipeline-and-cases/28665/Join Laura M. Periman, MD; Mile Brujic, OD, FAAO; and Jessica Steen, OD, FAAO, as they discuss dry eye disease. In this podcast, Dr. Periman talks about a few of the new and emerging dry eye disease therapies as well as the pipeline. Drs. Periman and Brujic also present cases. This content was captuPredispositions to Colorectal Cancer
https://reachmd.com/programs/advances-in-womens-health/predispositions-to-colorectal-cancer/2427/There is a dramatically uneven distribution of risk among women for colorectal cancer, the second most common cancer in America. Low-risk women have only five percent lifetime odds of developing the disease, while moderate and high-risk subsets are much more vulnerable. What accounts for this risk?Uncovering COVID-19 Treatments: An Update on the SOLIDARITY Trial
https://reachmd.com/programs/the-drug-report/uncovering-covid-19-treatments-an-update-on-the-solidarity-trial/11407/To find the most effective treatments for COVID-19, an international clinical trial was launched. Here’s the progress that’s been made so far.The Current State of Brazilian Butt Lifts
https://reachmd.com/ma-issues-index/2022-nov-dec/the-current-state-of-brazilian-butt-lifts/35227/Florida has become the world capital for BBLs. As mortality rates from the procedure raise concern, the Florida Board of Medicine aims to find ways to ensure safety.Pharmacology of Emerging Selective Sodium Channel Antagonists for the Treatment of Epilepsy
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/pharmacology-of-emerging-selective-sodium-channel-antagonists-for-the-treatment-of-epilepsy/39904/The development of isoform-selective sodium channel inhibitors that spare GABAergic interneuron function is in its early stages but holds promise as an exciting area of research.Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/Exploring CETP inhibition as the next breakthrough in lipid lowering, cardiologists highlight mechanisms, trials, and its role as a future CV therapy.